Prasterone versus vaginal estrogen: a different molecule, not an 'estrogen-free' shortcut

Prasterone and vaginal estradiol are different prescription products, not two names for the same local estrogen. Intrarosa contains prasterone, a steroid precursor, and is labeled for moderate-to-severe dyspareunia—a symptom of menopausal vulvar and vaginal atrophy. An estradiol vaginal cream contains estrogen and carries its own indication and warnings. Intrarosa’s label explicitly says estrogen is a metabolite of prasterone; calling it “estrogen-free” as a safety promise is misleading.¹²

Match the symptom to the label first

Pain with sexual activity, dryness, urinary symptoms, and other genitourinary complaints may be discussed together under genitourinary syndrome of menopause (GSM), but a specific prescription is labeled for a specific use. Intrarosa’s named indication is moderate-to-severe dyspareunia due to menopause. The comparator estradiol-cream label describes moderate-to-severe symptoms of vulvar and vaginal atrophy. A clinician should identify the primary symptom, assess whether another condition needs evaluation, and then compare exact products rather than promising that one “treats all GSM.”¹²

The Intrarosa label has a warning on current or past breast cancer, notes that estrogen is a metabolite of prasterone, and says the product has not been studied in women with a history of breast cancer. That does not establish it as a safer substitute for a survivor. ACOG’s survivor guidance requires a careful, oncology-aware process for persistent symptoms; the breast-cancer consultation guide treats that separate eligibility question directly.¹³

Do not turn an ingredient distinction into an outcome ranking

The labels explain what each finished product is and what it is approved to treat. They do not, by themselves, prove that one will work better for a particular patient’s symptoms or be safer for a particular medical history. Price, insurance coverage, convenience, and comfort using an insert versus cream may matter, but none can be responsibly guessed from a general comparison. Ask the practice to write down the exact proposed product, indication, and follow-up criteria.

This article is not the cream-versus-insert-versus-ring format guide. That page compares estrogen-product delivery formats. Here the active ingredient itself changes, as does the Intrarosa label’s specifically named symptom. Similarly, a local vaginal product should not be marketed as a treatment for systemic hot flashes without a separate indication assessment.

A focused provider question

Intrarosa’s distinct name can make it sound like a nonhormonal moisturizer. It is not: its active ingredient is a steroid precursor, and its label explains the estrogen-metabolite issue. That is why the product should be compared with local estrogen as a prescription hormonal option, not placed in a basket with over-the-counter lubricants or moisture products. The clinician should also explain why the named symptom—painful sex due to menopausal atrophy—fits, rather than treating every form of sexual pain as the same diagnosis.¹

If there is unexplained postmenopausal bleeding, the Intrarosa label says the cause should be evaluated before treatment is considered. The vaginal estradiol product has its own safety language. A changed symptom or bleeding pattern is a reason to pause the product-selection debate and seek clinical assessment. This is not a home test of which hormone precursor “feels gentler.”¹²

“Which symptom are we treating, what is the exact labeled indication for this product, and how does my medical and cancer history affect that choice?” If the answer rests entirely on “DHEA is natural” or “not estrogen,” request the actual Intrarosa labeling. Treomark’s hormone-therapy directory helps compare consultation access, while the prescriber must make the product decision with the full history.